<DOC>
	<DOCNO>NCT01863485</DOCNO>
	<brief_summary>This Phase I Dose-Escalation Study Evaluate Safety , Tolerability , Pharmacokinetics CM082 tablet Chinese Patients With Advanced Solid Tumors .</brief_summary>
	<brief_title>Phase 1 Study CM082 ( X-82 ) Tablets Advanced Cancer Patients China</brief_title>
	<detailed_description>This Phase I Dose-Escalation Study Evaluate Safety , Tolerability , Pharmacokinetics CM082 tablet Chinese Patients With Advanced Solid Tumors . After maximum tolerate dose ( MTD ) optimal biological dose identify , expansion cohort ~20 advance renal cell carcinoma patient enrol characterize safety tumor response CT .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis advance solid tumor malignancy responsive standard therapy effective therapy . Eastern Cooperative Group ( ECOG ) Performance Status score 0 1 . Life expectancy least 12 week . No immuno deficiency . Adequate organ system function , define follow : Absolute neutrophil count ( ANC ) ≥1.5 x 10**9/L Platelets ≥100 x 10**9/L Hemoglobin ≥10 g/dL Total bilirubin ≤1.5 time upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤1.5x upper limit normal ( ULN ) liver involvement ≤2.5x upper limit normal liver involvement . Creatinine ≤ 1.5 x ULN . At least 4 week 5 halflife receive cancer therapy ( i.e. , chemotherapy , radiation therapy , immunotherapy , biologic therapy , hormonal therapy , surgery and/or tumor embolization . Willingness ability comply trial followup procedure . Ability understand nature trial give write informed consent . Not recovered prior anticancer therapy surgery . Have take strong cytochrome P450 3A4 inhibitor inducer last 2 week . Concomitant use drug risk cause prolong correct QT interval and/or Torsades de Pointes . Patients history intolerance , significant toxicity , VEGFR tyrosine kinase inhibitor ( ) ( TKI ) . Females pregnant breastfeeding . Those reproductive age refuse use contraception . Those concurrent condition ( e.g . psychological , neuronal , cardiovascular , respiratory condition infection ) investigator 's opinion would jeopardize compliance protocol . Patients known central nervous system ( CNS ) metastases . Presence active gastrointestinal ( GI ) disease condition interfere significantly absorption , distribution , metabolism , excretion CM082 ( X82 ) . Patients know GI disorder vomit , diarrhea . Patients hepatitis B virus positive . Drug abuser .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>advanced cancer</keyword>
</DOC>